Cellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016

NEW YORK–(BUSINESS WIRE)– Regulatory News:

Cellectis S.A. Shareholders’ General Meeting (Paris:ALCLS) (NASDAQ:CLLS)
(Alternext: ALCLS – Nasdaq: CLLS) was held on Tuesday, May 17, 2016 in
Paris, at its head office.

At the meeting, during which more than 62% of voting rights were
exercised, 21 of 22 resolutions were adopted.

Each of the 21 resolutions, adopted in accordance with the
recommendation of the board of directors, received more than 75% votes
in favor. Resolution No. 22, regarding a capital increase reserved for
members of a company savings plan, was rejected in accordance with the
recommendation of the board of directors.

The resolutions adopted by Cellectis’ shareholders included:

• The approval of the financial statements for the financial year ended
  December 31, 2015
• The approval of specified related-party agreements
• The reappointment of Mr. Mathieu Simon to the board of directors
• Authorization of a share repurchase plan and authorization of the
  retirement of the shares acquired through it
• Delegations of authority given to the board of directors to increase
  share capital up to specified limits
• Resolutions authorizing Cellectis to grant its executive officers,
  employees, consultants and directors equity compensation up to
  specified limits

The full results of the vote can be examined on the company’s website (www.cellectis.com).

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering – based on its flagship TALEN^® products
and meganucleases and pioneering electroporation PulseAgile technology –
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it.
TALEN^® is a
registered trademark owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160519006527/en/